newsfilter
← Earnings
Earnings Releases·

Rani Therapeutics — Third Quarter 2026 Earnings Summary

  • Contract revenue reached $1.7 million for the three months ended September 30, 2026, compared to $0 in the prior year period, while net loss for the quarter widened to $8.8 million from $7.9 million.
  • Cash and marketable securities declined to $45.3 million as of September 30, 2026, from $53.4 million at the end of the second quarter, though management expects sufficient liquidity to fund operations through the end of 2027.
  • The RaniPill® Capsule platform was accepted into the FDA's Emerging Technology Program in October 2026, and additional data from the RT-114 Phase 1a expansion cohort is anticipated by the end of 2026.
  • Research and development expenses increased to $6.0 million for the quarter, driven primarily by higher compensation costs, while total liabilities decreased to $11.2 million from $17.1 million at the end of 2025.
Company
RANI THERAPEUTICS HOLDINGS INC
Sector
Healthcare
Industry
Biotechnology